Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.
about
Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite StudyKinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patientsUpdate on the treatment of patients with non-genotype 1 hepatitis C virus infectionUsefulness of the Hepatitis C Virus Core Antigen Assay for Screening of a Population Undergoing Routine Medical CheckupHepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses.Comparative Analysis of Anti-Hepatitis C Virus Activity and Gene Expression Mediated by Alpha, Beta, and Gamma InterferonsComparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5Comparative Evaluation of Three Commercially Available Methodologies for Hepatitis C Virus GenotypingA Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C PatientsExploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of itShort versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trialA multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variantsMathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entryNanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patientsLow- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingTherapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.Viral kinetics of enterovirus 71 in human abdomyosarcoma cellsTreatment of hepatitis C virus infectionA viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C.Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus.IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.Evolution of interferon-based therapy for chronic hepatitis C.Predicting the probable outcome of treatment in HCV patients.Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.Telaprevir-based treatment effects on hepatitis C virus in liver and blood.Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1.Review article: predicting response in hepatitis C virus therapy.Treatment of interferon-alpha for chronic hepatitis C.
P2860
Q24289102-A7C07032-27FE-4F70-A0D7-D8242D6B12D0Q25257004-7C7567F2-F7A8-4ED7-9006-960FEF4F07DEQ27000806-7E898CC5-B2FE-463B-8445-9B8ED5714FA6Q27469465-BD6BBC02-0491-473E-84D3-EFB68B3ABA03Q27472905-0950B796-A93A-49F8-9C1E-9BB13C640974Q27472908-555D23AF-5F61-4288-873A-CA50AA436A07Q27473038-0C42FB42-90BA-4EF6-AFA4-4EC43E8A0C5CQ27477505-03B06DE1-A0C7-412C-9218-0A6E15068581Q27481065-D2DE6563-E91F-4D6E-BEF9-EA991A78DD48Q27485351-DAB49DA8-5C92-4FC9-A965-7E9E223DB7D9Q27489046-9AAC1BB7-9FC7-4634-ADB3-10BC74E0442AQ27491047-16907B28-CFEA-4CFB-9033-10D2A15DDD50Q28473678-6D82AFEE-DB67-4FFA-BD54-406088D705BDQ28478310-1C54C5E4-2F75-4EDB-A572-E473B241DF79Q33559298-A7B14D9A-CC28-4FE5-AD74-4DE912F88557Q33675362-245B4A1B-16F9-4BCB-86DB-CC58D9624341Q33816657-2B084046-EAA9-4FE1-A9BB-A12AFD913640Q33899320-7E78118B-8A9A-4A18-93BE-0936C9566D0FQ33999004-FB8C9FC1-6652-457F-869C-A14BB8A10279Q34062108-B2589FB1-EF89-4FF7-9F26-3D849D4D1359Q34099424-32A02A01-4C93-4752-ABAA-AA706E9A2809Q34126254-6E426C90-DDF3-48A2-AC73-379FE1CD0063Q34182392-C830CE37-7389-4FEC-83F1-0758E5618AC1Q34247627-687B3C72-672C-498C-81B0-A47318F7919CQ34251341-188958C8-52A5-47F3-841B-8D40CFC4D6ABQ34255562-BAF7C00B-10CD-4D79-9FA4-058FA5872F42Q34342092-C1A4AC6E-0361-45CA-A078-EAD30A489131Q34409039-87BE29FB-F369-4698-81B0-1E50959F8DB4Q34488497-BF9A5DE3-14E1-4F68-A0F9-0945DE837ABEQ34532854-2C5BAF0E-038E-46C1-A6BC-BF49E969D997Q34621423-48161AC5-24EE-4EE2-B52D-D12A51FEC6B7Q35093280-0128A739-E04C-419A-ADFF-5CFE638845E6Q35095217-E2D728F9-75DB-4390-96DB-3F0B94DEE2A5Q35129251-D70D8FDF-0777-41AD-8879-6D8BE4665E99Q35597434-91BB7E86-8E13-4D24-8090-706306B84681Q35610571-0ED974EF-20E9-4FB4-A891-F75838F32619Q35771879-6112B85C-3118-4F42-B478-21F925A5091AQ36012993-5846DB3C-484D-4DC0-818D-2A6281D7A0B6Q36447562-F9AFC510-B07D-4B7D-8699-88C68536BFEBQ36491803-44A2F9D0-6078-46FE-BF12-8062F80B4CF7
P2860
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Viral kinetics in patients wit ...... dard or peginterferon alpha2a.
@en
Viral kinetics in patients wit ...... dard or peginterferon alpha2a.
@nl
type
label
Viral kinetics in patients wit ...... dard or peginterferon alpha2a.
@en
Viral kinetics in patients wit ...... dard or peginterferon alpha2a.
@nl
prefLabel
Viral kinetics in patients wit ...... dard or peginterferon alpha2a.
@en
Viral kinetics in patients wit ...... dard or peginterferon alpha2a.
@nl
P2093
P356
P1433
P1476
Viral kinetics in patients wit ...... dard or peginterferon alpha2a.
@en
P2093
A U Neumann
E Herrmann
P304
P356
10.1053/GAST.2001.24006
P407
P577
2001-05-01T00:00:00Z